RLYB
NASDAQ HealthcareRallybio Corporation - Common Stock
Biotechnology
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
๐ Market Data
| Price | $16.23 |
|---|---|
| Volume | 180,041 |
| Market Cap | 94.13M |
| RSI (14-Day) | 65.7 |
| 200-Day MA | $6.95 |
| 50-Day MA | $11.10 |
| 52-Week High | $17.57 |
| 52-Week Low | $2.16 |
| Forward P/E | -3.01 |
| Price / Book | 1.71 |
๐ฏ Investment Strategy Scores
RLYB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (78/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RLYB in your text
Paste any article, transcript, or post โ the tool will extract RLYB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.